CD4 and pneumocystosis: In the guidelines recommended by the National Institutes of Health, the Centers for Disease Control and Prevention, and the HIV Medicine Association of the Infectious Diseases Society of America [8], HIV-infected patients should receive trimethoprim-sulfamethoxazole (TMP-SMX) as primary prophylaxis for pneumocystosis if they have CD4 counts of <200 cells/μL.